Den europeiske union - rumensk - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - folitropin delta - anovulația - hormoni sexuali și modulatori ai sistemului genital, - controlate de stimulare ovariana pentru dezvoltarea de foliculi mai multe femei fac obiectul tehnologii de reproducere asistată (art), cum ar fi o fertilizare in vitro (fiv) sau injectare intracitoplasmatica a spermei (icsi) ciclu.

Den europeiske union - rumensk - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - agenți antineoplazici - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Den europeiske union - rumensk - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - hemipentahidrat de pemetrexed disodic - carcinoma, non-small-cell lung; mesothelioma - agenți antineoplazici - malignant pleural mesothelioma ciambra in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer ciambra in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. ciambra este indicat în monoterapie pentru tratamentul de întreținere de la nivel local avansat sau metastatic cu celule non-mici cancer pulmonar altul decât predominant tipul histologic cu celule scuamoase la pacienții a căror boală nu a progresat imediat după chimioterapie pe bază de platină. ciambra este indicat ca monoterapie pentru cea de-a doua linie de tratament a pacienților cu local avansat sau metastatic cu celule non-mici cancer pulmonar altul decât predominant tipul histologic cu celule scuamoase.

Den europeiske union - rumensk - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil clorhidrat de - neoplasme colorectale - agenți antineoplazici - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Den europeiske union - rumensk - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - carcinom, pulmonar non-celulă mică - agenți antineoplazici - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Den europeiske union - rumensk - EMA (European Medicines Agency)

amgen europe bv - sotorasib - carcinom, pulmonar non-celulă mică - agenți antineoplazici - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Den europeiske union - rumensk - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - agenți antineoplazici - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Den europeiske union - rumensk - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - agenți antineoplazici - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Den europeiske union - rumensk - EMA (European Medicines Agency)

advanced accelerator applications - luteţiu (177lu) oxodotreotide - tumori neuroendocrine - alte produse radiofarmaceutice terapeutice - lutathera este indicat pentru tratamentul unresectable sau metastatic, progresivă, bine diferentiat (g1 și g2), somatostatina receptorilor pozitiv gastroenteropancreatic neuroendocrine tumori (gep‑nets) la adulti.

Romania - rumensk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

advanced accelerator applications (italy) s.r.l. - italia - gallium (68ga) gozetotida - trusa (kit) pt. preparate radiofarmaceutice - 25micrograme - preparate pentru detectarea tumorilor alte radiofarmaceutice pt. detectarea tumorilor